VANTAGE / SEE MORE · EARLY PREVIEW WITH SAMPLE DATA
VANTAGE / PHARMA FIELD INTELLIGENCE

Not one customer.
Three conversations.

Field teams visit physicians, hospitals and pharmacies. Their decisions, needs, contacts and next steps are different — the commercial context stays connected.

Explore the three journeys ↘
SALES REP / TODAY03
01 / Physician

Product adoption

Trial follow-up

↗
02 / Hospital

Stakeholder network

Access decision

↗
03 / Pharmacy

Branch & pharmacist

Availability review

↗
Same CRM / different tasks and recommendations
02 / VANTAGE PHARMA

Different stakeholders.
One intelligent field process.

Every interaction follows the specific doctor, institution and product — not a generic call cycle.

PRODUCT INTELLIGENCE ILLUSTRATIVE FIELD RECORD
THREE COMMERCIAL CONTEXTS
PhysicianFirst visit → Trial · Stage-specific approved content
HospitalDepartment access · Stakeholder context & approvals
PharmacyAvailability & adoption · Branch-level follow-up
PRODUCT AAdoption progression
01First visit
02Trial
03User
04Regular
05Heavy
06KOL
VANTAGE / CONTENT MATCHProduct A · evidence for the next visit

Match approved materials to product and adoption stage.

PRODUCT B
Trial

Illustrative concept · KOL and heavy use remain distinct stages

VANTAGE PHARMA / THREE REAL FIELD JOURNEYS

The visit changes.
The intelligence follows.

Choose who your representative is visiting. See how the commercial context, evidence and relevant action changes — without switching software.

01 / PRODUCT × CONTACT

Physician

BEFORE THE VISIT

A physician is trialling Product B. A visit was documented, but feedback remains open.

01 / What VANTAGE notices

A product-specific adoption milestone is due. Not every medicine has the same adoption stage for this physician.

02 / A meaningful next step

Prepare a trial follow-up, review approved evidence and document the outcome.

03 / Relevant material

Approved product guide, medical information and objection-specific material.

Related capabilitiesAccount 360 · contact history · product adoption · visit · approved materials

Fictional scenarios. No patient information or pharmacy dispensing data is implied. Engagement, claims and material use require appropriate permissions and regulatory review.

THE FIELD NOTES / PHARMA

The work after
the visit matters.

Rehearse a follow-up for three different customer types. The relevant evidence changes with the institution and visit outcome. Nothing here writes to a CRM.

VANTAGE / VISIT REVIEW / DEMO
Context-specific follow-up

Material / evidence to review

Suggested owner

Illustrative only. Product materials must be appropriately approved. No patient information, dispensing records, or clinical advice.

ACCOUNT HIERARCHY / ONE CRM

The relationship has more than one level.

An institution, a site, a department and an individual contact are different records with distinct responsibilities.

ORGANISATIONHealthcare group
↓
Hospital A / Hospital B
↓
Department · Purchasing · HCPs
↔ONE CRM
ORGANISATIONPharmacy group
↓
Pharmacy branch
↓
Pharmacist · Team · Visit
PHARMA INTELLIGENCE

The customer relationship is product-specific.

Each relationship has a separate adoption stage for every product.

CONTACT × PRODUCT × COMPANY

One doctor. Different product journeys.

Select a product to reveal the stage, next interaction and relevant repository material.

PRODUCT DEVELOPMENT

Product A · regular user

Review usage history and select evidence for continued adoption.


RECOMMENDED MATERIAL / ILLUSTRATIVE

Product A / evidence summary

01First Visit
02Trial
03User
04Regular User
05Heavy User
06KOL

Heavy User and KOL are explicitly distinct. KOL requires documented scientific influence. Example data only.

01 / PHARMA TASK

Before the visit

See product-specific stage, contact history, relevant objections and approved materials.

02 / PHARMA TASK

During & after

Document genuine visit outcomes, competitor signals and the next milestone.

03 / PHARMA TASK

Management

Review stage progression, coverage, sales, opportunities and evidence.

01

The six-stage adoption ladder

First Visit → Trial → User → Regular User → Heavy User → KOL. The stage is specific to each contact, product and authorised company. Heavy user and KOL are different roles.

02

An organised product repository

Match stage-appropriate, approved and versioned product material to the doctor’s current conversation. Evidence and access permissions matter.

03

Field intelligence that compounds

Capture visit outcomes, access restrictions, new stakeholders and competitor developments as attributable signals, then evaluate the next appropriate interaction.

A customer relationship has several product stories

One physician may be a regular user of Product A and only evaluating Product B. Pharmaceutical adoption cannot be represented accurately by a single doctor-level status. VANTAGE models the ladder by authorised company, contact and product.

The agreed stages are First Visit, Trial, User, Regular User, Heavy User and KOL. Heavy use describes sustained product engagement; KOL is a separate scientifically documented influence role, not an automatic sales-volume promotion.

Different audiences need different account structures

Doctors require contact-by-product adoption records; hospitals require institution, site, department, procurement and stakeholder structures; pharmacies require branches, responsible pharmacists and their visit history.

A hospital procurement process or pharmacy staff-training need should not be forced into the same adoption-stage ladder as an individual prescriber.

Plan the right next interaction

Before a visit, a representative needs the contact’s history, the product’s adoption stage, recorded objections, previous materials and planned milestone. After a visit, the representative should be able to record a genuine outcome and update the relevant product-stage evidence.

The next recommended step should be tailored: education after an initial visit, discussion of experience after trial, sustained-use support for regular users, or scientific engagement appropriate to a documented KOL.

Materials follow the adoption stage

A product repository should hold approved, versioned and audience-appropriate materials. The representative can find the right document for the product and stage rather than searching through unrelated files.

Medical, promotional, consent and country-specific rules still govern actual communications. Clinical claims and outreach require appropriate human and regulatory review.

Managers need more than call counts

Evaluate completed and credited visits, required frequency, territory potential, product-stage progression, commercial results and observed access barriers. Rising activity with stagnant adoption may indicate an education gap or a product-fit problem rather than insufficient effort.

VANTAGE Pharma is an optional specialist module. Ordinary visit planning, account records, routes and the core intelligence dashboard remain part of Intelligent CRM.

VANTAGE / NEXT

Your next move is the interesting part.

See how commercial information can become a clearer plan.

Request a demo